MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Sangamo Therapeutics Inc

Suletud

SektorTervishoid

0.8 6.67

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.73

Max

0.83

Põhinäitajad

By Trading Economics

Sissetulek

-34M

-23M

Müük

-42M

7.6M

Aktsiakasum

-0.11

Kasumimarginaal

-309.84

Töötajad

183

EBITDA

-34M

-24M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+517.28% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-45M

165M

Eelmine avamishind

-5.87

Eelmine sulgemishind

0.8

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Sangamo Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. dets 2024, 11:35 UTC

Suurimad hinnamuutused turgudel

Sangamo Shares Rally Premarket on License Deal With Astellas

Võrdlus sarnastega

Hinnamuutus

Sangamo Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

517.28% tõus

12 kuu keskmine prognoos

Keskmine 5 USD  517.28%

Kõrge 10 USD

Madal 2 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Sangamo Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

5

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.7379 / 0.8298Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.